In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: A critical role for tissue macrophages

Journal of Infectious Diseases

Volumn 184, Issue 4, 2001, Pages 479-487

  Grinsell, Matthew ^a,b   Weinhold, Leanne C ^a   Cutler, Jim E ^c   Han, Yongmoon ^c   Kozel, Thomas R ^b  

^a Department of Microbiology ^*  (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; GLUCURONOXYLOMANNAN; LIPOSOME; MANNAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLEARANCE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FEMALE; FUNGAL MENINGITIS; HALF LIFE TIME; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRULENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; CRYPTOCOCCUS NEOFORMANS; FEMALE; IMMUNIZATION, PASSIVE; KIDNEY; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; POLYSACCHARIDES; SPLEEN; TISSUE DISTRIBUTION;

EID: 0035882455     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/322787     Document Type: Article

References (50)

1. Polysaccharide antigens of the capsule of Cryptococcus neoformans
2. Cryptococcus neoformans. I. Nonencapsulated mutants
3. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans
4. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans
5. Cryptococcus neoformans. III. Inhibition of phagocytosis
6. Inhibition of phagocytosis by cryptococcal polysaccharide: Dissociation of the attachment and ingestion phases of phagocytosis
7. Immune response to Cryptococcus neoformans soluble polysaccharide: Immunological unresponsiveness
8. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique
9. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation
10. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils
11. Cryptococcal polysaccharides bind to CD18 on human neutrophils
12. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome
13. The fine structure of cerebral fluid accumulation. III. Extracellular spread of cryptococcal polysaccharides in the acute stage
14. The fine structure of cerebral fluid accumulation. IV. On the nature and origin of extracellular fluids following cryptococcal polysaccharide implantation
15. Interleukin-6 production of human monocytes stimulated with Cryptococcus neoformans components
16. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils
17. Downregulation by cryptococcal polysaccharide of tumor necrosis factor α and interleukin-1β secretion from human monocytes
18. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes
19. Enhancement of HIV-l infection by the capsular polysaccharide of Cryptococcus neoformans
20. Enhancement of HIV type 1 Infectivity in vitro by capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae
21. Detection of Cryptococcus neoformans antigen in body fluids by latex particle agglutination
22. Comparison of the Premier cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens
23. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome
24. Prognostic factors in cryptococcal meningitis: A study of 111 cases
25. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: Diagnostic features and outcome of treatment
26. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
27. Cryptococcal meningitis: Outcome in patients with AIDS and patients with neoplastic disease
28. Cryptococcal infections in patients with acquired immune deficiency syndrome
29. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide
30. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody
31. Rapid clearance of Candida albicans mannan antigens by liver and spleen in contrast to prolonged circulation of Cryptococcus neoformans antigens
32. The course of cryptococcal capsular polysaccharide antigenemia/human cryptococcal polysaccharide elimination kinetics
33. Cryptococcal capsular polysaccharide clearance in nonimmune mice
34. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis
35. The liposome-mediated macrophage "suicide" technique
36. Characteristics of antibodies in normal human serum that are reactive with the Cryptococcus neoformans glucuronoxylomannan
37. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide
38. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis
39. Organ plasma volume of normal unanesthetized mice
40. Distribution of blood (Fe59) and plasma (I131) volumes of rats determined by liquid nitrogen freezing
41. The blood volume of mammals as determined by experiments upon rabbits, guinea-pigs and mice, and its relationship to the body weight and surface area expressed in a formula
42. Binding of Candida albicans yeast cells to mouse popliteal lymph node tissue is mediated by macrophages
43. Improved methods for the preparation of the specific polysaccharides of pneumococcus
44. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans
45. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule
46. Reactivity of Cryptococcus neoformans and Candida species with concanavalin A and blood grouping sera
47. 125I-labeled SSS-II to study serum antibody levels, as well as the distribution and excretion of antigen after immunization
48. Cryptococcal antigen detection from the urine of AIDS patients
49. Immunoglobulin A-mediated hepatobiliary transport constitutes a natural pathway for disposing of bacterial antigens
50. Decomposition of the capsular polysaccharide of Cryptococcus neoformans 3723 by a soil microorganism